Samidorphan: Difference between revisions
CSV import |
CSV import |
||
| Line 31: | Line 31: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Samidorphan structure.svg|Samidorphan | |||
</gallery> | |||
Latest revision as of 01:49, 20 February 2025
Samidorphan (also known as ALKS-33) is a drug that acts as a potent and selective antagonist for the mu-opioid receptor. It is being developed by Alkermes for the treatment of addiction and other disorders, and has reached Phase II clinical trials for binge eating disorder and major depressive disorder.
History[edit]
Samidorphan was first developed by Alkermes, a biopharmaceutical company. It was initially investigated for its potential in treating addiction and other disorders. The drug has undergone Phase II clinical trials for binge eating disorder and major depressive disorder.
Pharmacology[edit]
Samidorphan is a potent and selective antagonist for the mu-opioid receptor. This means it blocks the action of opioids at these receptors, which can help to reduce the effects of opioid addiction.
Clinical trials[edit]
Samidorphan has undergone Phase II clinical trials for the treatment of binge eating disorder and major depressive disorder. The results of these trials are not yet available.
Potential uses[edit]
The primary potential use for Samidorphan is in the treatment of addiction, particularly opioid addiction. By blocking the action of opioids at the mu-opioid receptor, Samidorphan could help to reduce the effects of opioid addiction. It is also being investigated for potential use in treating binge eating disorder and major depressive disorder.
